All In Biotech

Investigational drug · Phase 3

Azetukalner

Also called: XEN1101

Not approved by FDA. In 9 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Focal Onset Seizures, Major Depressive Disorder, Bipolar Disorder.

Phase 3

Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

9

8 still active

All registered trials

9

Any phase or sponsor naming "Azetukalner"

First trial start

2019

Jan 30, 2019

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Azetukalner", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Focal Onset Seizures
  • Major Depressive Disorder
  • Bipolar Disorder
  • Bipolar Depression
  • Bipolar I Disorder
  • Bipolar II Disorder
  • Focal Epilepsy
  • Tonic-Clonic Seizures
  • Primary Generalized Tonic-Clonic Seizures

Approved drugs for the same conditions: Epilepsy and seizures · Depression (major depressive disorder) · Bipolar disorder · Neurology · Psychiatry

Largest trials

Live from ClinicalTrials.gov: studies naming "Azetukalner" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 27 on PubMed

Also in development for Focal Onset Seizures

  • RAP-219Phase 35 trials

    Rapport Therapeutics Inc. · Focal Epilepsy, Epilepsy, Focal Seizure

  • SPN-817BIS-001ER, Huperzine APhase 24 trials

    Supernus Pharmaceuticals, Inc. · Focal Onset Seizures, Focal Impaired Awareness Seizures, Epilepsy

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.